166 related articles for article (PubMed ID: 38760419)
1. Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system.
Zhu H; Wu M
Sci Rep; 2024 May; 14(1):11262. PubMed ID: 38760419
[TBL] [Abstract][Full Text] [Related]
2. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
3. A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab.
Yun X; Zhou Y; Wu D; Liu Y; Wu Q
Expert Opin Drug Saf; 2024 May; 23(5):581-591. PubMed ID: 38600747
[TBL] [Abstract][Full Text] [Related]
4. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
5. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
[TBL] [Abstract][Full Text] [Related]
6. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
7. Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System.
Zhao D; Long X; Wang J
Expert Opin Drug Saf; 2024 May; 23(5):599-605. PubMed ID: 38553867
[TBL] [Abstract][Full Text] [Related]
8. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
[TBL] [Abstract][Full Text] [Related]
9. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
[TBL] [Abstract][Full Text] [Related]
10. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.
Yin G; Song G; Xue S; Liu F
Sci Rep; 2024 May; 14(1):11367. PubMed ID: 38762547
[TBL] [Abstract][Full Text] [Related]
11. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
[TBL] [Abstract][Full Text] [Related]
12. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
Zhang S; Wang Y; Qi Z; Tong S; Zhu D
Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
[TBL] [Abstract][Full Text] [Related]
13. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
[TBL] [Abstract][Full Text] [Related]
14. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
Shu Y; Chen J; Ding Y; Zhang Q
Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
[TBL] [Abstract][Full Text] [Related]
15. A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin.
Xu Z; Huang D; Liu Q; Liu S; Liu J; Wang H; Shen Z
Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38695550
[TBL] [Abstract][Full Text] [Related]
16. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
[TBL] [Abstract][Full Text] [Related]
17. Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.
Li Y; Wang X; Liao Y; Zeng Y; Lin W; Zhuang W
BMC Infect Dis; 2024 May; 24(1):446. PubMed ID: 38724914
[TBL] [Abstract][Full Text] [Related]
18. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
19. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
[TBL] [Abstract][Full Text] [Related]
20. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
